Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma”

8 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 8 of 8 results

Testing effectiveness (Phase 2)Study completedNCT02250885
What this trial is testing

KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors

Who this might be right for
Carcinoma, Neuroendocrine
Gabrail Cancer Center Research 14
Testing effectiveness (Phase 2)Study completedNCT02955069
What this trial is testing

Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)

Who this might be right for
Well-differentiated Non-functional NET of Thoracic OriginWell-differentiated Non-functional NET of Gastrointestinal OriginWell-differentiated Non-functional NET of Pancreatic Origin+1 more
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)Study completedNCT03591731
What this trial is testing

Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs)

Who this might be right for
Neuroendocrine Carcinoma
Intergroupe Francophone de Cancerologie Thoracique 185
Testing effectiveness (Phase 2)Active Not RecruitingNCT02595424
What this trial is testing

Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

Who this might be right for
Gastric Neuroendocrine CarcinomaIntestinal Neuroendocrine CarcinomaPancreatic Neuroendocrine Carcinoma
ECOG-ACRIN Cancer Research Group 67
Early research (Phase 1)Looking for participantsNCT07080242
What this trial is testing

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

Who this might be right for
Small Cell Lung Cancer Metastatic or Locally AdvancedNeuroendocrine CancerMetastatic or Locally Advanced Neuroendocrine Prostate Cancer+5 more
SystImmune Inc. 120
Testing effectiveness (Phase 2)Enrolling By InvitationNCT05385861
What this trial is testing

Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET

Who this might be right for
GEP-NET
National Health Research Institutes, Taiwan 52
Testing effectiveness (Phase 2)Looking for participantsNCT04325425
What this trial is testing

Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary

Who this might be right for
Neuroendocrine Carcinoma
Centre Hospitalier Universitaire Dijon 218
Large-scale testing (Phase 3)Looking for participantsNCT06937905
What this trial is testing

Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)

Who this might be right for
Neuroendocrine Carcinoma
Intergroupe Francophone de Cancerologie Thoracique 129
116